Entero Healthcare Solutions Limited , a leading healthcare supply chain solutions provider, has reported robust financial performance for the second quarter and half-year ended September 30, 2025, while also announcing significant strategic acquisitions to expand its market presence.

Financial Highlights

For Q2 FY26, Entero Healthcare Solutions reported consolidated revenue from operations of Rs. 15,709.48 crore, marking a substantial increase from Rs. 13,006.92 crore in the corresponding quarter of the previous year. The company's profit after tax for the quarter stood at Rs. 366.00 crore, up from Rs. 260.33 crore in Q2 FY25.

The half-yearly results were equally impressive, with consolidated revenue reaching Rs. 29,747.67 crore, compared to Rs. 23,977.28 crore in H1 FY25. The profit after tax for H1 FY26 increased to Rs. 668.32 crore from Rs. 465.63 crore in the same period last year.

Key Financial Metrics

The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for Q2 FY26 improved to Rs. 777.21 crore, with an EBITDA margin of 4.95%, showing an improvement in operational efficiency.

Strategic Acquisitions

Entero Healthcare Solutions announced two significant acquisitions to strengthen its market position:

1. Bioaide Technologies Private Limited: The company will acquire an 80% stake in Bioaide Technologies, a Delhi-based distributor of medical devices and healthcare products. The acquisition, valued between Rs. 31.13 crore to Rs. 36 crore, is expected to be completed by February 15, 2026.

2. Anand Chemiceutics Private Limited: Entero has entered into a binding Memorandum of Understanding to acquire a 51% stake in Anand Chemiceutics, a Pune-based wholesale distributor of medical devices. The deal, valued between Rs. 210 crore to Rs. 230 crore, is subject to due diligence and is expected to be completed in FY26.

These acquisitions align with Entero's strategy to expand its distribution network and product portfolio in the healthcare sector.

Corporate Updates

The company also announced several corporate updates:

• Allotment of 2,030 equity shares under the Employee Stock Option Plan 2023, increasing the total paid-up equity share capital to Rs. 43,51,09,370.
• Appointment of Mr. Abhitesh Kumar as Chief Growth Officer, elevating him from his previous role as President – Retail Business & New Initiatives.
• Successful utilization of IPO proceeds, with Rs. 930.07 crore deployed out of the total Rs. 951.33 crore raised.

Management Commentary

Prabhat Agrawal, Promoter, Managing Director and CEO of Entero Healthcare Solutions, commented on the results: "The quarter reflects continuation of strong growth trajectory and margin expansion. We achieved an EBITDA Margin of 4% in the quarter through focus on gross margin expansion along with improvement in net working capital days. As we complete the first half of the year, we remain on-track to deliver on our full-year guidance."

Agrawal added, "We are expanding significantly in the MedTech segment through new acquisitions which marked a pivotal step forward- a move that creates meaningful synergies with our existing pharmaceutical distribution and enhances our overall margin profile."

The company's focus on inorganic growth and operational efficiency appears to be yielding positive results, positioning Entero Healthcare Solutions for continued growth in the evolving healthcare distribution landscape.

Investors and stakeholders will be watching closely to see how these strategic moves translate into long-term value creation for the company.

Entero Healthcare Solutions Limited has reported robust financial performance for the second quarter of fiscal year 2025-26, along with plans for strategic acquisitions to further strengthen its market position in the healthcare distribution sector.

Q2 Financial Highlights

For the quarter ended September 30, 2025, Entero Healthcare Solutions posted impressive results:

• Consolidated net profit rose to Rs 316.00 million, up from Rs 236.00 million in the same quarter last year, marking a 33.90% year-over-year increase.
• Revenue surged to Rs 15.71 billion from Rs 13.00 billion in the corresponding period, representing a 20.80% growth.
• EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to Rs 621.00 million from Rs 425.00 million year-over-year.
• EBITDA margin improved to 3.95% from 3.26% in the same quarter last year.

Strategic Acquisitions

In a move to expand its market reach and product portfolio, Entero Healthcare Solutions announced plans for two significant acquisitions:

1. Bioaide Technologies Private Limited: The company has entered into definitive agreements to acquire an 80% stake in Bioaide Technologies. The acquisition, valued between Rs 311.30 million to Rs 360.00 million, is expected to be completed by February 15, 2026. Bioaide specializes in the wholesale distribution of medical devices and healthcare products.

2. Anand Chemiceutics Private Limited: Entero has signed a binding Memorandum of Understanding to acquire a 51% stake in Anand Chemiceutics. The deal, estimated between Rs 2.10 billion to Rs 2.30 billion, is subject to due diligence and final agreements. Anand Chemiceutics is engaged in wholesale distribution of medical devices and turnkey projects for healthcare institutions.

Management Commentary

Prabhat Agrawal, CEO & Managing Director of Entero Healthcare Solutions, stated, "Our strong Q2 performance reflects the robust demand in the healthcare sector and our ability to efficiently meet market needs. The planned acquisitions of Bioaide Technologies and Anand Chemiceutics align with our growth strategy and will significantly enhance our distribution capabilities and product offerings."

Organizational Changes

The company also announced the elevation of Mr. Abhitesh Kumar to the position of Chief Growth Officer. Previously serving as President – Retail Business & New Initiatives, Mr. Kumar's new role is expected to drive Entero's expansion plans further.

Market Outlook

With these strategic moves, Entero Healthcare Solutions is positioning itself for continued growth in the competitive healthcare distribution market. The acquisitions are expected to complement the company's existing operations and contribute to its long-term revenue and profitability goals.

Investors and industry observers will be watching closely to see how these acquisitions integrate with Entero's operations and impact its market position in the coming quarters.